Seeking to boost biosimilar uptake, Pfizer Inc. is asking FDA to issue guidance to deter innovator companies from suggesting that biosimilars are not as safe and effective as reference biologics.
In an Aug. 22 citizen petition, Pfizer requests that the agency publish a guidance document that describes the types of sponsor communications about reference products and biosimilars – including interchangeable biologics – that would be false or misleading